109 related articles for article (PubMed ID: 37055936)
1. Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerations.
Moorthy G; Pouliot GP; Graham L; Pilling E; Jung L; Alcobi R; Zhu Y; Li Y; Sidhu S; Forte P; Mugundu G
Br J Clin Pharmacol; 2023 Sep; 89(9):2775-2787. PubMed ID: 37055936
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
[TBL] [Abstract][Full Text] [Related]
3. The effect of food and acid-reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study.
Miller C; Sommavilla R; Murphy D; Morris T; Khatun M; Cullberg M
Br J Clin Pharmacol; 2023 Nov; 89(11):3330-3339. PubMed ID: 37328269
[TBL] [Abstract][Full Text] [Related]
4. Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers.
Rioux N; Kim A; Nix D; Bowser T; Warmuth M; Smith PG; Schindler J
Cancer Chemother Pharmacol; 2019 Jan; 83(1):91-96. PubMed ID: 30368584
[TBL] [Abstract][Full Text] [Related]
5. Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (Qelbree
Wang Z; Kosheleff AR; Adeojo LW; Odebo O; Liranso T; Schwabe S; Nasser A
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):69-79. PubMed ID: 34652564
[TBL] [Abstract][Full Text] [Related]
6. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
7. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
8. Effect of Food on the Bioavailability of Omadacycline in Healthy Participants.
Tzanis E; Manley A; Villano S; Tanaka SK; Bai S; Loh E
J Clin Pharmacol; 2017 Mar; 57(3):321-327. PubMed ID: 27539539
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
Tomkinson H; McBride E; Martin P; Lisbon E; Dymond AW; Cantarini M; So K; Holt D
Clin Ther; 2017 Nov; 39(11):2260-2275.e1. PubMed ID: 28985960
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
[TBL] [Abstract][Full Text] [Related]
11. Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants.
Shimizu H; Nishimura Y; Shiide Y; Akimoto M; Matsuda H; Kato Y; Hirai M
Clin Ther; 2022 Dec; 44(12):1552-1565. PubMed ID: 36376130
[TBL] [Abstract][Full Text] [Related]
12. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
[TBL] [Abstract][Full Text] [Related]
13. Results From Phase I Studies Investigating the Dose Linearity of Finerenone Tablets and the Influence of Food or pH-Modifying Comedications on its Pharmacokinetics in Healthy Male Volunteers.
Heinig R; Nagelschmitz J; Loewen S
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):549-559. PubMed ID: 35612708
[TBL] [Abstract][Full Text] [Related]
14. Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An
Piscitelli J; Hens B; Tomaszewska I; Wollenberg L; Litwiler K; McAllister M; Reddy M
Mol Pharm; 2023 May; 20(5):2589-2599. PubMed ID: 37037186
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.
Shaik N; Hee B; Wei H; LaBadie RR
Cancer Chemother Pharmacol; 2019 Mar; 83(3):463-472. PubMed ID: 30536154
[TBL] [Abstract][Full Text] [Related]
16. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects.
Crockett J; Critchley D; Tayo B; Berwaerts J; Morrison G
Epilepsia; 2020 Feb; 61(2):267-277. PubMed ID: 32012251
[TBL] [Abstract][Full Text] [Related]
17. Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males.
Li J; Tan Y; Li K; Hui AM; Wu Z; Han P; Wei Z; Qiu J; Diao L; Wang X
Adv Ther; 2023 Mar; 40(3):1074-1086. PubMed ID: 36627544
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect.
Caras S; Sharpe T
J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):69-80. PubMed ID: 31809216
[No Abstract] [Full Text] [Related]
20. Effects of a High-fat Meal on the Pharmacokinetics of the VEGFR Inhibitor Fruquintinib: A Randomized Phase I Study in Healthy Subjects.
Qian H; Fan S; Li K; Sai Y; Su W; Chen Q; Liu Y; Li T; Wang W; Jia J; Yu C; Liu Y
Clin Ther; 2019 Aug; 41(8):1537-1544. PubMed ID: 31272709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
